FY2027 Earnings Estimate for MRK Issued By Erste Group Bank

Merck & Co., Inc. (NYSE:MRK) – Research analysts at Erste Group Bank lifted their FY2027 EPS estimates for shares of Merck & Co., Inc. in a report released on Monday, July 27th. Erste Group Bank analyst H. Engel now expects that the company will post earnings of $9.54 per share for the year, up from their prior forecast of $9.52. The consensus estimate for Merck & Co., Inc.’s current full-year earnings is $2.74 per share.

MRK has been the topic of a number of other reports. Wall Street Zen downgraded shares of Merck & Co., Inc. from a “buy” rating to a “hold” rating in a report on Monday, July 20th. Bank of America raised their price objective on shares of Merck & Co., Inc. from $130.00 to $141.00 and gave the stock a “buy” rating in a report on Tuesday, June 30th. Royal Bank Of Canada reiterated an “outperform” rating and issued a $142.00 target price on shares of Merck & Co., Inc. in a research note on Wednesday, July 8th. Scotiabank increased their target price on shares of Merck & Co., Inc. from $136.00 to $155.00 and gave the company a “sector outperform” rating in a research report on Tuesday, June 30th. Finally, Citigroup initiated coverage on shares of Merck & Co., Inc. in a research note on Wednesday, May 6th. They set a “neutral” rating and a $125.00 price target for the company. Thirteen investment analysts have rated the stock with a Buy rating and seven have assigned a Hold rating to the company’s stock. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average price target of $134.50.

Merck & Co., Inc. Trading Down 1.0%

Shares of Merck & Co., Inc. stock opened at $130.45 on Thursday. The firm has a market cap of $322.18 billion, a PE ratio of 36.75, a P/E/G ratio of 5.23 and a beta of 0.19. Merck & Co., Inc. has a 1 year low of $77.53 and a 1 year high of $135.05. The company has a debt-to-equity ratio of 1.02, a current ratio of 1.30 and a quick ratio of 1.06. The stock has a fifty day moving average price of $122.73 and a 200-day moving average price of $118.24.

Merck & Co., Inc. (NYSE:MRK) last issued its quarterly earnings results on Thursday, April 30th. The company reported ($1.28) EPS for the quarter, topping analysts’ consensus estimates of ($1.47) by $0.19. Merck & Co., Inc. had a return on equity of 27.55% and a net margin of 13.59%.The business had revenue of $16.29 billion for the quarter, compared to analyst estimates of $15.85 billion. During the same period last year, the company posted $2.22 earnings per share. Merck & Co., Inc.’s quarterly revenue was up 4.9% compared to the same quarter last year.

Merck & Co., Inc. Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Wednesday, October 7th. Investors of record on Tuesday, September 15th will be paid a dividend of $0.85 per share. This represents a $3.40 dividend on an annualized basis and a dividend yield of 2.6%. The ex-dividend date is Tuesday, September 15th. Merck & Co., Inc.’s payout ratio is presently 95.77%.

Institutional Trading of Merck & Co., Inc.

Institutional investors have recently added to or reduced their stakes in the stock. Somerset Trust Co grew its stake in Merck & Co., Inc. by 0.9% during the second quarter. Somerset Trust Co now owns 8,701 shares of the company’s stock valued at $1,118,000 after acquiring an additional 81 shares in the last quarter. Stonebridge Financial Group LLC grew its position in Merck & Co., Inc. by 0.9% during the second quarter. Stonebridge Financial Group LLC now owns 8,747 shares of the company’s stock worth $1,124,000 after buying an additional 81 shares in the last quarter. Stronghold Wealth Management L.L.C. grew its position in Merck & Co., Inc. by 2.6% during the second quarter. Stronghold Wealth Management L.L.C. now owns 3,237 shares of the company’s stock worth $416,000 after buying an additional 82 shares in the last quarter. Lederer & Associates Investment Counsel CA increased its stake in Merck & Co., Inc. by 0.9% in the 2nd quarter. Lederer & Associates Investment Counsel CA now owns 9,603 shares of the company’s stock worth $1,234,000 after acquiring an additional 84 shares during the last quarter. Finally, Pine Haven Investment Counsel Inc increased its stake in Merck & Co., Inc. by 0.6% in the 2nd quarter. Pine Haven Investment Counsel Inc now owns 14,273 shares of the company’s stock worth $1,834,000 after acquiring an additional 86 shares during the last quarter. Hedge funds and other institutional investors own 76.07% of the company’s stock.

Key Headlines Impacting Merck & Co., Inc.

Here are the key news stories impacting Merck & Co., Inc. this week:

• Positive Sentiment: Barclays raises price target: Barclays increased its target for MRK from $140 to $150 and maintained an “overweight” rating, implying approximately 15% upside from the referenced share price. Barclays raises Merck price target
• Positive Sentiment: Higher long-term earnings forecast: Erste Group Bank raised its FY2027 earnings estimate for Merck to $9.54 per share from $9.52, a modestly favorable revision that suggests some confidence in the company’s longer-term outlook.
• Positive Sentiment: Ebola vaccine manufacturing initiative: Hilleman Laboratories, the Merck-Wellcome joint venture, is preparing to manufacture doses of an experimental vaccine targeting the Bundibugyo strain of Ebola for clinical trials. The effort could strengthen Merck’s public-health profile and create longer-term commercial opportunities, although it is not an immediate earnings driver. Merck and Wellcome Ebola vaccine partnership
• Neutral Sentiment: Dividend reaffirmed: Merck declared a quarterly dividend of $0.85 per share, payable October 7 to investors of record September 15. The annualized yield is approximately 2.6%, supporting the stock’s income appeal but offering little new information because the payment was expected. Merck announces fourth-quarter dividend
• Negative Sentiment: Upcoming earnings remain a concern: Analysts expect Merck’s second-quarter earnings to decline, and recent previews suggest the company lacks the factors typically associated with a likely earnings beat. This may be weighing on sentiment ahead of the report, despite the favorable longer-term estimate revision. Merck earnings preview

About Merck & Co., Inc.

Merck & Co, Inc is a global biopharmaceutical company engaged in the discovery, development, manufacture and marketing of prescription medicines, vaccines, biologic therapies and animal health products. Its portfolio spans multiple therapeutic areas with a particular emphasis on oncology, vaccines and infectious disease, as well as therapies for metabolic and chronic conditions. Among its well-known products are the cancer immunotherapy Keytruda (pembrolizumab) and the human papillomavirus vaccine Gardasil; the company also markets a range of medicines and vaccines for veterinary use through Merck Animal Health.

Founded in the late 19th century as the U.S.